Aethlon Medical has appointed Timothy Rodell as its interim CEO, the company announced Thursday. Rodell was previously president and CEO of Louisville, CO-based GlobeImmune from 2002 to 2016. He remains a GlobeImmune director and consultant. GlobeImmune was acquired last year by NantCell, a subsidiary of Patrick Soon-Shiong’s NantWorks. Rodell succeeds Aethlon’s (NASDAQ: [[ticker:AEMD]]) Jim Joyce. Aethlon has designed a device, the Hemopurifier, that it is testing as a treatment for cancer and life-threatening viral infections.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
